Results 111 to 120 of about 59,823 (200)
Microbiota–Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma
Brain and Behavior, Volume 16, Issue 8, August 2026.Microbiota–neuroinflammation crosstalk in GBM. The schematic summarizes how gut microbiota and microbiota‐derived signals may influence GBM biology through gut–brain signaling, microbial metabolites, systemic immune modulation, BBB‐related pathways, tumor‐associated microbial signals, and immune‐metabolic changes within the GBM microenvironment.
Tareq Nayef AlRamadneh +8 more
wiley +1 more source
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy +10 more
wiley +1 more source
Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma
Cancer Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways ...
Ali Nakhaei +5 more
wiley +1 more source
Epilepsia Open, Volume 11, Issue 4, Page 1137-1148, August 2026.Abstract Objective High‐grade astrocytomas, including glioblastomas, are aggressive brain tumors with poor prognosis and a 5‐year survival below 7%. Seizures affect up to 75% of glioma patients, especially in low‐grade tumors but also in high‐grade cases.
Matteo Impellizzeri +7 more
wiley +1 more source
Autophagy Modulation in Cancer Therapy: Navigating the Dual Roles to Overcome Chemoresistance
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background Autophagy is a fundamental cellular recycling mechanism with complex and often opposing roles in cancer, functioning as both a tumor suppressor and a pro‐survival mechanism in established tumors. This duality has attracted considerable attention, particularly regarding the therapeutic modulation of autophagy to overcome ...
Md Mohiuddin, Md Al Mamun Ahsan
wiley +1 more source
Medical Physics, Volume 53, Issue 8, August 2026.Abstract Background Glioblastoma (GB) is an aggressive primary brain tumor with local recurrence rates exceeding 90% and a five‐year survival rate of approximately 5%. Standard treatments such as surgical resection, external beam radiotherapy (EBRT), and chemotherapy often leave residual tumor cells that are resistant to therapy.
Maram El Sabri +4 more
wiley +1 more source
Small Science, Volume 6, Issue 8, August 2026.Quantum‐capacitance biosensing enables real‐time monitoring of naxitamab in patient samples via laser‐fabricated electrodes and single‐point calibration. The proposed platform provides rapid and sensitive quantification, with the potential to enable therapeutic drug monitoring and patient stratification according to circulating naxitamab levels, while ...
Andy Bruno +8 more
wiley +1 more source
Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment
Immunology &Cell Biology, Volume 104, Issue 7, Page 711-728, August 2026.Three interconnected processes in glioblastoma (GBM) biology: initiation, stratification, and immunosuppression. 1) Initiation: GBM initiation is proposed to occur through migration of TERT mutation‐bearing neural stem cells from the subventricular zone to the frontal and temporal cortices, where a subsequent oncogenic transformation drives their ...
Emerson Achari +6 more
wiley +1 more source
Can acromegaly be controlled in all cases?
Journal of Neuroendocrinology, Volume 38, Issue 8, August 2026.Abstract Acromegaly is a rare disease, due in most of the cases to a growth hormone (GH)‐secreting pituitary adenoma (PA), namely neuroendocrine tumour (PitNET). The treatment of patients with acromegaly is multimodal and multi‐step, including surgery, medical therapies, and radiotherapy.
Sabrina Chiloiro +14 more
wiley +1 more source
Cancer, Volume 132, Issue 14, 15 July 2026.ABSTRACT Background Chemotherapy schemes have historically shown low efficacy in patients with metastatic melanoma and have been replaced by immunotherapy and targeted therapy. This work aimed to study whether chemotherapy remains an option after progression to immunotherapy in specific contexts.
Miguel‐Ángel Berciano‐Guerrero +29 more
wiley +1 more source